{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:07:21Z","timestamp":1760731641345,"version":"3.33.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Emodepside is an anthelmintic used in veterinary medicine that is currently under investigation in human clinical trials for the treatment of soil-transmitted helminths and possibly <jats:italic>Onchocerca volvulus<\/jats:italic>. Emodepside targets the calcium-activated voltage-gated potassium slowpoke 1 (SLO-1) channels of presynaptic nerves of pharynx and body wall muscle cells of nematodes leading to paralysis, reduced locomotion and egg laying, starvation, and death. Emodepside also has activity against <jats:italic>Drosophila melanogaster<\/jats:italic> SLO-1 channels. Orthologous SLO-1 genes are present in <jats:italic>Anopheles gambiae<\/jats:italic> and <jats:italic>Aedes aegypti<\/jats:italic>, suggesting that emodepside may have activity against mosquitoes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Both <jats:italic>Anopheles dirus<\/jats:italic> and <jats:italic>Ae. aegypti<\/jats:italic> were blood-fed emodepside across a range of concentrations (1\u201310,000\u00a0nM) and mosquito survival was monitored for 10\u00a0days. Co-feeding experiments were also performed with <jats:italic>An. dirus<\/jats:italic> blood fed ivermectin at the concentrations that kills 25% (LC<jats:sub>25<\/jats:sub>) and 50% (LC<jats:sub>50<\/jats:sub>) of mosquitoes with and without emodepside at clinical peak concentration in humans (C<jats:sub>max<\/jats:sub>) and five times the C<jats:sub>max<\/jats:sub>, and mosquito survival was monitored for 10\u00a0days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Emodepside had weak mosquito-lethal effects in <jats:italic>An. dirus<\/jats:italic> but none observed in <jats:italic>Ae. aegypti<\/jats:italic> at the concentrations evaluated. The <jats:italic>An. dirus<\/jats:italic> emodepside LC<jats:sub>50<\/jats:sub> was 4,623 [4,159\u20135,066] ng\/ml which is\u2009&gt;\u2009100-fold greater than the peak concentrations seen in human. The ivermectin and emodepside co-feed experiment with <jats:italic>An. dirus<\/jats:italic> did not indicate any altered effect of ivermectin on mosquito survival when emodepside co-fed at human C<jats:sub>max<\/jats:sub> or five times that of the human C<jats:sub>max<\/jats:sub>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Emodepside was not lethal to <jats:italic>An. dirus<\/jats:italic> at human-relevant concentrations and had no effect on <jats:italic>Ae. aegypti<\/jats:italic> survival. Thus, mass distribution of emodepside does not appear to be a potential tool for vector-borne disease control. Emodepside induced mortality in <jats:italic>An. dirus<\/jats:italic> does suggest that the SLO-1 channel could be a potential target for novel vector control and may warrant further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12936-025-05250-8","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:32:23Z","timestamp":1736933543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential of emodepside for vector-borne disease control"],"prefix":"10.1186","volume":"24","author":[{"given":"Pattarapon","family":"Khemrattrakool","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thitipong","family":"Hongsuwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theerawit","family":"Phanphoowong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patchara","family":"Sriwichai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kittiyod","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"Kobylinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"5250_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijpddr.2021.07.005","volume":"17","author":"M H\u00fcbner","year":"2021","unstructured":"H\u00fcbner M, Townson S, Gokool S, Tagboto S, Maclean M, Verocai G, et al. Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside. Int J Parasitol Drugs Drug Resist. 2021;17:27\u201335.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5250_CR2","doi-asserted-by":"publisher","first-page":"e1009601","DOI":"10.1371\/journal.ppat.1009601","volume":"17","author":"G Bah","year":"2021","unstructured":"Bah G, Schneckener S, Hahnel S, Bayang N, Fieseler H, Schmuck G, et al. Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis. PLoS Pathog. 2021;17:e1009601.","journal-title":"PLoS Pathog"},{"key":"5250_CR3","doi-asserted-by":"publisher","first-page":"e1009682","DOI":"10.1371\/journal.ppat.1009682","volume":"17","author":"J Kr\u00fccken","year":"2021","unstructured":"Kr\u00fccken J, Holden-Dye L, Keiser J, Prichard R, Townson S, Makepeace B, et al. Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration. PLoS Pathog. 2021;17:e1009682.","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"5250_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s00436-005-1438-z","volume":"97","author":"A Harder","year":"2005","unstructured":"Harder A, Holden-Dye L, Walker R, Wunderlich F. Mechanisms of action of emodepside. Parasitol Res. 2005;97(Suppl 1):S1\u201310.","journal-title":"Parasitol Res"},{"key":"5250_CR5","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1111\/bcp.14816","volume":"87","author":"J Gillon","year":"2021","unstructured":"Gillon J, Dennison J, van den Berg F, Delhomme S, Dequatre Cheeseman K, Pe\u00f1a Rossi C, et al. Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects. Br J Clin Pharmacol. 2021;87:3949\u201360.","journal-title":"Br J Clin Pharmacol"},{"key":"5250_CR6","doi-asserted-by":"publisher","first-page":"e0010219","DOI":"10.1371\/journal.pntd.0010219","volume":"16","author":"F Assmus","year":"2022","unstructured":"Assmus F, Hoglund R, Monnot F, Specht S, Scandale I, Tarning J. Drug development for the treatment of onchocerciasis: population pharmacokinetic and adverse events modeling of emodepside. PLoS Negl Trop Dis. 2022;16:e0010219.","journal-title":"PLoS Negl Trop Dis"},{"key":"5250_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fvets.2019.00296","volume":"6","author":"D Gaens","year":"2019","unstructured":"Gaens D, Leith\u00e4user C, Hamann M, Geyer J. Adverse drug reactions after administration of emodepside\/praziquantel (Profender\u00ae) in an MDR1-mutant Australian shepherd dog: case report. Front Vet Sci. 2019;6:296.","journal-title":"Front Vet Sci"},{"key":"5250_CR8","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa2212825","volume":"388","author":"E Mrimi","year":"2023","unstructured":"Mrimi E, Welsche S, Ali S, Hattendorf J, Keiser J. Emodepside for Trichuris trichiura and hookworm Infection. N Engl J Med. 2023;388:1863\u201375.","journal-title":"N Engl J Med"},{"key":"5250_CR9","unstructured":"Drugs for Neglected Diseases. Emodepside Phase II Trial for Treatment of Onchocerciasis (NCT05180461) ClinicalTrials.gov2022 https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05180461."},{"key":"5250_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ijpara.2006.10.013","volume":"37","author":"K Bull","year":"2007","unstructured":"Bull K, Cook A, Hopper N, Harder A, Holden-Dye L, Walker R. Effects of the novel anthelmintic emodepside on the locomotion, egg-laying behaviour and development of Caenorhabditis elegans. Int J Parasitol. 2007;37:627\u201336.","journal-title":"Int J Parasitol"},{"key":"5250_CR11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.ijpara.2007.05.006","volume":"37","author":"M Guest","year":"2007","unstructured":"Guest M, Bull K, Walker R, Amliwala K, O\u2019Connor V, Harder A, et al. The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans. Int J Parasitol. 2007;37:1577\u201388.","journal-title":"Int J Parasitol"},{"key":"5250_CR12","doi-asserted-by":"publisher","first-page":"e0004062","DOI":"10.1371\/journal.pntd.0004062","volume":"9","author":"A Crisford","year":"2015","unstructured":"Crisford A, Ebbinghaus-Kintscher U, Schoenhense E, Harder A, Raming K, O\u2019Kelly I, et al. The cyclooctadepsipeptide anthelmintic emodepside differentially modulates nematode, insect and human calcium-activated potassium (SLO) channel alpha subunits. PLoS Negl Trop Dis. 2015;9:e0004062.","journal-title":"PLoS Negl Trop Dis"},{"key":"5250_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S0031182004006523","volume":"130","author":"G von Samson-Himmelstjerna","year":"2005","unstructured":"von Samson-Himmelstjerna G, Harder A, Sangster N, Coles G. Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic-resistant nematodes in sheep and cattle. Parasitol. 2005;130:343\u20137.","journal-title":"Parasitol"},{"key":"5250_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijpddr.2020.04.003","volume":"13","author":"P Jimenez Castro","year":"2020","unstructured":"Jimenez Castro P, Mansour A, Charles S, Hostetler J, Settje T, Kulke D, et al. Efficacy evaluation of anthelmintic products against an infection with the canine hookworm (Ancylostoma caninum) isolate Worthy 4.1F3P in dogs. Int J Parasitol Drugs Drug Resist. 2020;13:22\u20137.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5250_CR15","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1186\/s13071-024-06294-6","volume":"17","author":"P Khemrattrakool","year":"2024","unstructured":"Khemrattrakool P, Hongsuwong T, Tipthara P, Kullasakboonsri R, Phanphoowong T, Sriwichai P, et al. Impact of ivermectin components on Anopheles dirus and Anopheles minimus mosquito survival. Parasit Vectors. 2024;17:e224.","journal-title":"Parasit Vectors"},{"key":"5250_CR16","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.3390\/insects13070658","volume":"13","author":"N Sutthanont","year":"2022","unstructured":"Sutthanont N, Sudsawang M, Phanpoowong T, Sriwichai P, Ruangsittichai J, Rotejanaprasert C, et al. Effectiveness of herbal essential oils as single and combined repellents against Aedes aegypti, Anopheles dirus and Culex quinquefasciatus (Diptera: Culicidae). Insects. 2022;13:e658.","journal-title":"Insects"},{"key":"5250_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.19-0620","volume":"102","author":"P Billingsley","year":"2020","unstructured":"Billingsley P, Binka F, Chaccour C, Foy B, Gold S, Gonzalez-Silva M, et al. A roadmap for the development of ivermectin as a complementary malaria vector control tool. Am J Trop Med Hyg. 2020;102:3\u201324.","journal-title":"Am J Trop Med Hyg"},{"key":"5250_CR18","first-page":"179","volume":"44","author":"J Whitehorn","year":"2013","unstructured":"Whitehorn J, Thi L, le Dui T, Simmons C. Aedes aegypti (L.) survival after exposure to ivermectin. Southeast Asian J Trop Med Public Health. 2013;44:179\u201381.","journal-title":"Southeast Asian J Trop Med Public Health"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05250-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05250-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05250-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:32:26Z","timestamp":1736933546000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05250-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5250"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05250-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human study protocol was approved by the ethics committees of the Faculty of Tropical Medicine, Mahidol University (TMEC 23-078) and deferred by the Oxford University Tropical Research Ethics Committee. The animal study protocol was approved by the Animal Care and Use Committee of the Faculty of Tropical Medicine, Mahidol University (024-2023). All experiments were performed in accordance with the relevant guidelines and regulations of the above listed institutions. Each blood donor volunteer was provided with an explanation of the study and signed a written informed consent before study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}